Leo Fontenot, Huili Yao, Alexanndra M. Behm, Anabel Soldano, Fabrizio Donnarumma, Richard A. Bunce and Mario Rivera*,
{"title":"Inhibiting Bacterioferritin Iron Release Induces Iron Starvation and Metabolic Downshift, Potentiating Aminoglycosides in P. aeruginosa Biofilms","authors":"Leo Fontenot, Huili Yao, Alexanndra M. Behm, Anabel Soldano, Fabrizio Donnarumma, Richard A. Bunce and Mario Rivera*, ","doi":"10.1021/acsinfecdis.6c00329","DOIUrl":null,"url":null,"abstract":"<p >In <i>Pseudomonas aeruginosa</i>, bacterioferritin contributes to regulating cytosolic iron by oxidizing Fe<sup>2+</sup> and storing Fe<sup>3+</sup> within its internal cavity, and binding to its cognate ferredoxin to reduce stored Fe<sup>3+</sup> and release Fe<sup>2+</sup> to the cytosol. Small molecule derivatives of 4-aminoisoindoline-1,3-dione bind <i>P. aeruginosa</i> bacterioferritin at the cognate ferredoxin binding site, inhibit iron release from bacterioferritin, and exhibit bactericidal activity against mature <i>P. aeruginosa</i> biofilms. In this study we report that treatment of mature biofilms with the 4-aminoisoindoline-1,3-dione derivative KM-5-35 induced approximately 90% cell death. Proteomic analysis of surviving cells revealed iron limitation accompanied by disrupted central carbon metabolism, reduced fatty acid and amino acid biosynthesis, and alterations in ribosome protein composition. These metabolic downshifts likely resulted in unstable proton motive force, diminished efflux capacity and impaired ribosome turnover. In this compromised state, gentamicin and amikacin, but not tobramycin, efficiently exploit KM-5-35-induced translational stress, leading to profound synergistic killing of biofilm cells. These findings underscore the therapeutic potential of targeting bacterioferritin iron mobilization in biofilm-associated infections and suggest a promising strategy for combination antimicrobial therapy.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":"12 7","pages":"2358–2371"},"PeriodicalIF":4.5000,"publicationDate":"2026-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.6c00329","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsinfecdis.6c00329","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
In Pseudomonas aeruginosa, bacterioferritin contributes to regulating cytosolic iron by oxidizing Fe2+ and storing Fe3+ within its internal cavity, and binding to its cognate ferredoxin to reduce stored Fe3+ and release Fe2+ to the cytosol. Small molecule derivatives of 4-aminoisoindoline-1,3-dione bind P. aeruginosa bacterioferritin at the cognate ferredoxin binding site, inhibit iron release from bacterioferritin, and exhibit bactericidal activity against mature P. aeruginosa biofilms. In this study we report that treatment of mature biofilms with the 4-aminoisoindoline-1,3-dione derivative KM-5-35 induced approximately 90% cell death. Proteomic analysis of surviving cells revealed iron limitation accompanied by disrupted central carbon metabolism, reduced fatty acid and amino acid biosynthesis, and alterations in ribosome protein composition. These metabolic downshifts likely resulted in unstable proton motive force, diminished efflux capacity and impaired ribosome turnover. In this compromised state, gentamicin and amikacin, but not tobramycin, efficiently exploit KM-5-35-induced translational stress, leading to profound synergistic killing of biofilm cells. These findings underscore the therapeutic potential of targeting bacterioferritin iron mobilization in biofilm-associated infections and suggest a promising strategy for combination antimicrobial therapy.
期刊介绍:
ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to:
* Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials.
* Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets.
* Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance.
* Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents.
* Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota.
* Small molecule vaccine adjuvants for infectious disease.
* Viral and bacterial biochemistry and molecular biology.